Chairman:
Jarosław Błaszczak
Vice Chairman:
Wiktor Napióra
Members:
Waldemar Sierocki
Dariusz Kucowicz
Dirk Pamperina
Konrad Miterski
Maciej Siedlar
Maciej Korniluk
Shareholder structure as of 13.08.2020.
The table below presents the shareholder structure with a special list of shareholders having at least 5% of share of votes on the General Meeting of the Company (in accordance with shareholders’ notifications from Art. 69 on Public Offering and ESPI reports on shareholders with at least 5% of total votes on the Issuer’s General Meetings).
| Shareholder | Number of shares (% in SC) | Number of votes (% in GM) |
|---|---|---|
| Waldemar Sierocki | 4 790 504 (7,69%) | 9 325 588 (11,51%) |
| Przemysław Sierocki | 4 785 083 (7,69%) | 9 320 166 (11,50%) |
| Organizacja Polskich Dystrybutorów Farmaceutycznych S.A. | 5 068 157 (8,14%) | 5 068 157 (6,26%) |
| Wiktor Napióra | 4 922 623 (7,91%) | 9 695 628 (11,97%) |
| Dariusz Kucowicz total* | 5 523 005 (8,87%) | 10 296 010 (12,71%) |
| Other <5% | 37 171 038 (59,70%) | 37 313 841 (46,06%) |
| SUM | 62 260 410 (100,00%) | 81 014 390 (100,00%) |
Investor’s calendar
Transferring periodical reports in 2020 shall be on the following dates:
REPORT DATE OF PUBLICATION
annual report for the financial year 2019 . . . . . . . . . . . . . . . . 18 March 2020
quarterly report for the 1st quarter of 2020 . . . . . . . . . . . . 11 May 2020
semi-annual report for the 1st half of 2020 . . . . . . . . . . . . . . . 14 September 2020
quarterly report for the 3rd quarter of 2020 . . . . . . . . . . . . . . . 9 November 2020
According to § 101 sec. 2 of the Decree of the Minister of Finance dated 19 February 2009 on current and periodic information provided by issuers of securities and conditions for recognising as equivalent the information required by the law of a non-member state (Dz. U. [Journal of Laws] 2014 no. 0 item 133) the Company shall not publish the quarterly report for the 4th quarter of 2017 and for the 2nd quarter of 2018.
Information concerning closed periods
Regulation (EU) no. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC (MAR Regulation) introduces the concept of so called closed periods.
According to art. 19 sec. 11 a person discharging managerial responsibilities in a Company (i.e. Members of Supervisory Board and Management Board) cannot make any transactions on own account or on behalf of a third party, directly or indirectly, concerning shares or debt financial instruments of an issuer or derivative instruments or other financial instruments concerning them, for the closed period of 30 calendar days before publishing of a periodical report.
Pursuant to art. 19 sec. 12 of the MAR Regulation in the circumstances referred to in the regulation, the Company may allow the person discharging managerial responsibilities to make transactions on own account or on behalf of third party during the closed period.
Furthermore, according to the MAR Regulation, persons having access to confidential information, before it is published, shall be prohibited especially from:
use of confidential information,
disclosing confidential information to unauthorised persons and entities,
giving recommendations or inducing to acquire or dispose of financial instruments,
make transactions involving securities issued by the Company and derivative instruments, attempt to engage in such trading as well as modify or cancel the orders after acquiring confidential information.
For all cases concerning Investor Relations please contact:
Chief Financial Officer
Radosław Wróblewski
e-mail.: rwroblewski@biomedlublin.com
Address:
“BIOMED-LUBLIN” Wytwórnia Surowic i Szczepionek Spółka Akcyjna
20-029 Lublin ul. Uniwersytecka 10
